MedTrace Logo

Quality of Life in Patients With HCV Related Liver Cirrhosis Before and After Direct Acting Antiviral Drugs

NCT03897608 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-02-11

No results posted yet for this study

Summary

To evaluate the effects of DAAs on HRQL in patients with liver cirrhosis secondary to chronic HCV infection

Conditions

  • HCV Related Liver Cirrhosis Direct Acting Antiviral Drugs

Interventions

BEHAVIORAL

short form 36

The Short Form (SF)-36 Health Survey was used to measure HRQL. The SF-36 generates a profile of HRQL outcomes by measuring health across eight different dimensions: physical functioning, role limitation because of physical health, social functioning, vitality, bodily pain, mental health, role limitation because of emotional problems and general health. Responses to each question within a dimension are combined to generate a score from 0to100; where100 indicates "good health"

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
11 Months
Max Age
12 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2020-07-01
Completion
2020-09-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03897608 on ClinicalTrials.gov